Hot off the Press September 2024
We have collated some great articles and material published over the last month. Click on the links below to read the abstract or download the full paper.
Anatomy / Physiology /Pathophysiology
The emerging importance of lymphangiogenesis in aging and aging-associated diseases
RC Ji – Mechanisms of Ageing and Development, 2024
Prevalence and Risk Factors
Clinical, Pathologic, and Dosimetric Predictors of Head and Neck Lymphedema Following Definitive or Adjuvant Radiation Therapy for Head and Neck Cancer
Risk Profiling of Breast Cancer-Related Lymphedema (BCRL) in Patients With Breast Cancer Via Using Body Composition and Tissue Dielectric Constant (TDC) Method: A Cross-Sectional Study
The Effects of Daily-Living Risks on Breast Cancer-Related Lymphedema
MR Fu, B Liu, JM Qiu, Y Sun, D Axelrod, A Guth… – Annals of Surgical Oncology, 2024
Characteristics of lymphoedema, in particular midline lymphoedema, after treatment for prostate cancer: a retrospective study
Incidence of lymphedema related to various cancers
ME Letellier, M Ibrahim, A Towers, G Chaput – Med Oncol 41, 245 (2024)
Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation- click for abstract
Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation
A Engin – Advances in experimental medicine and biology, 2024
Several studies show that a significantly stronger association is obvious between increased body mass index (BMI) and higher breast cancer incidence. Additionally, obese and postmenopausal women are at higher risk of all-cause and breast cancer-specific mortality compared with non-obese women with breast cancer. In this context, increased levels of estrogens, excessive aromatization activity of the adipose tissue, overexpression of pro-inflammatory cytokines, insulin resistance, adipocyte-derived adipokines, hypercholesterolemia, and excessive oxidative stress contribute to the development of breast cancer in obese women. Genetic evaluation is an integral part of diagnosis and treatment for patients with breast cancer. Despite trimodality therapy, the four-year cumulative incidence of regional recurrence is significantly higher. Axillary lymph nodes as well as primary lesions have diagnostic, prognostic, and therapeutic significance for the management of breast cancer. In clinical setting, because of the obese population primary lesions and enlarged lymph nodes could be less palpable, the diagnosis may be challenging due to misinterpretation of physical findings. Thereby, a nomogram has been created as the “Breast Imaging Reporting and Data System” (BI-RADS) to increase agreement and decision-making consistency between mammography and ultrasonography (USG) experts. Additionally, the “breast density classification system,” “artificial intelligence risk scores,” ligand-targeted receptor probes,” “digital breast tomosynthesis,” “diffusion-weighted imaging,” “18F-fluoro-2-deoxy-D-glucose positron emission tomography,” and “dynamic contrast-enhanced magnetic resonance imaging (MRI)” are important techniques for the earlier detection of breast cancers and to reduce false-positive results. A high concordance between estrogen receptor (ER) and progesterone receptor (PR) status evaluated in preoperative percutaneous core needle biopsy and surgical specimens is demonstrated. Breast cancer surgery has become increasingly conservative; however, mastectomy may be combined with any axillary procedures, such as sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection whenever is required. As a rule, SLNB-guided axillary dissection in breast cancer patients who have clinically axillary lymph node-positive to node-negative conversion following neoadjuvant chemotherapy is recommended, because lymphedema is the most debilitating complication after any axillary surgery. There is no clear consensus on the optimal treatment of occult breast cancer, which is much discussed today. Similarly, the current trend in metastatic breast cancer is that the main palliative treatment option is systemic therapy.
Breast cancer-related lymphedema: A comprehensive analysis of risk factors - click for abstract
Breast cancer-related lymphedema: A comprehensive analysis of risk factors
C Siotos, SH Arnold, M Seu, L Lunt, J Ferraro… – Journal of surgical oncology. 2024 Aug 27. doi: 10.1002/jso.27841.
Background: Breast cancer-related lymphedema is a devastating condition that negatively affects the quality of life of breast cancer survivors. We sought to identify risk factors that predicted the timing and development of lymphedema.
Methods: Women with breast cancer that underwent sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) at our institution between 2007 and 2022 were identified and sociodemographic and clinical information was extracted. We used logistic regression analysis to identify risk factors for lymphedema and performed cox-regression analysis to predict the timing of lymphedema presentation after surgery.
Results: We identified 1,223 patients, of which 161 (13.2%) developed lymphedema within 1.8 (mean, SD = 2.5) years postoperatively. Patients with SLNB had significantly lower odds for lymphedema development (vs. ALND, OR = 0.29 [0.14-0.57]). Patients between 40 and 49 years of age, and 50-59 (vs. <40 years, OR = 2.14 [1.00-4.60]; OR = 2.42, [1.13-5.16] respectively), African American patients (vs. Caucasian, OR = 1.86 [1.12-3.09]), patients with stage II, III, and IV disease (vs. stage 0, OR = 3.75 [1.36-10.33]; OR = 6.62 [2.14-20.51]; OR = 9.36 [2.94-29.81]), and patients with Medicaid (vs. private insurance, OR = 3.56 [1.73-7.28]) had higher rates of lymphedema. Cox-regression analysis showed that African American (HR = 1.71 [1.08-2.70]), higher BMI (HR = 1.03 [1.00-1.06]), higher stage (stage II, HR = 2.22 [1.05-7.09]; stage III, HR = 5.26 [1.86-14.88]; stage IV, HR = 6.13 [2.12-17.75]), and Medicaid patients (HR = 2.15 [1.12-3.80]) had higher hazards for lymphedema. Patients with SLNB had lower hazards for lymphedema (HR = 0.43 [0.87-2.11]). Conclusion: Lymphedema has identifiable risk factors that can reliably be used to predict the chances of lymphedema development and enable clinicians to educate patients better and formulate treatment plans accordingly.
Assessment
Lower Extremity Lymphatic Flow/Drainage Assessment by Indocyanine Green Fluorescent Lymphography in Heart Failure Patients
Arm symptom pattern among breast cancer survivors with and without lymphedema: a contemporaneous network analysis
Current diagnostic and quantitative techniques in the field of lymphedema management: a critical review
Development and Validation of Upper Limb Lymphedema in Patients After Breast Cancer Surgery Using a Practicable Machine Learning Model: A Retrospective Cohort Study
The Role of Body Composition Analyzer in the Preoperative Assessment of Breast Cancer Patients
L Zhang, Q Zhong, Y Ding, J Li, Q Luo, L Zhang, Y Guo… – Journal of Cancer Therapy, 2024
Skin mechanical properties measured with skin elasticity measurement device in patients with lymphedema: Scoping review
Y Fujimoto, Y Yuri, H Tamiya – Skin Research and Technology, 2024
Assessment Modalities for Lower Extremity Edema, Lymphedema, and Lipedema: A Scoping Review
M Biura, T Carel, K Moreira, P Sneha, M Neethu… – Cureus, 2024
Factors Predicting the Effect of a Complex Decongestive Therapy in Patients with Mild Lymphedema Following Mastectomy for Early Stage Breast Cancer - click for abstract
Factors Predicting the Effect of a Complex Decongestive Therapy in Patients with Mild Lymphedema Following Mastectomy for Early Stage Breast Cancer
Relation Between Characteristics of Indocyanine Green Lymphography and Development of Breast Cancer-Related Lymphedema - click for abstract
Relation Between Characteristics of Indocyanine Green Lymphography and Development of Breast Cancer-Related Lymphedema
Current Diagnostic Measures for Lymphedema: A Comprehensive Review - click for abstract
Current Diagnostic Measures for Lymphedema: A Comprehensive Review
Analysis of Different Lymphedema Assessment Tools in Women with Breast Cancer After Mastectomy - click for abstract
Analysis of Different Lymphedema Assessment Tools in Women with Breast Cancer After Mastectomy
Management Strategies
Resources on lymphedema surgery: How effective are they for patients? - click for abstract
Resources on lymphedema surgery: How effective are they for patients?
The effects of the-optimal-lymph-flow health IT system application on treatment-related high risk lymphedema in breast cancer patients: a randomized controlled trial - click for abstract
The effects of the-optimal-lymph-flow health IT system application on treatment-related high risk lymphedema in breast cancer patients: a randomized controlled trial
Breast cancer-related arm lymphoedema: a critical unmet need
Closing the Gaps: An Integrative Review of Yoga’s Benefits for Lymphedema in Breast Cancer Survivors
Results from A Comparative Study to Evaluate the Treatment Effectiveness of a Non-Pneumatic Compression Device versus an Advanced Pneumatic Compression Device for Lower Extremity Lymphedema Swelling (TEAYS study)
Efficacy of intermittent pneumatic compression on breast cancer-related upper limb lymphedema: a systematic review and meta-analysis in clinical studies
Adjustable Velcro® compression devices as compared to 4-layer compression bandages for the treatment of venous leg ulcers and optimisation of patient satisfaction
Sharon L Boxall, Keryln Carville, Joanna Smith, Shirley Jansen. Wound Practice and Research. 2024;32(3):120-128. DOI 10.33235/wpr.32.3.8-120-128
Primary LYmphedema Multidisciplinary Approach in Patients Affected by Primary Lower Extremity Lymphedema
Evidence for the clinical effectiveness of decongestive lymphoedema treatment for breast cancer–related arm lymphoedema, a systematic review
E Jeffs, E Ream, C Taylor, A Purushotham, D Bick – Supportive Care in Cancer, 2024